This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Exact Sciences Gets FDA Nod for Label Expansion of Cologuard
by Zacks Equity Research
Exact Sciences (EXAS) gets FDA approval for use of its noninvasive colorectal cancer screening test, Cologuard, in eligible average-risk individuals aged 45 years or older.
Zacks Value Trader Highlights: Exact Sciences, Edwards Lifesciences, Bristol Myers-Squibb, Occidental Petroleum and Exxon Mobil
by Zacks Equity Research
Zacks Value Trader Highlights: Exact Sciences, Edwards Lifesciences, Bristol Myers-Squibb, Occidental Petroleum and Exxon Mobil
Stock Investors: Do You Need a Late Cycle Plan?
by Tracey Ryniec
The financial media keeps talking about the economy being in the late cycle but that doesn't mean you can't be buying stocks.
The Zacks Analyst Blog Highlights: Bristol-Myers Squibb Company, Celgene, Exact Sciences, Pfizer and Guardant Health
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Bristol-Myers Squibb Company, Celgene, Exact Sciences, Pfizer and Guardant Health
3 Cancer Treatment Stocks to Enrich Your Portfolio
by Tirthankar Chakraborty
Investments in cancer therapies are expected to rise almost $250 billion by 2023, from $150 billion in 2018. Thus, companies that are coming up with innovative methods to cure this malaise are great investment choices.
Exact Sciences (EXAS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Exact Sciences (EXAS) delivered earnings and revenue surprises of 46.43% and 9.86%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Exact Sciences (EXAS) Q2 Earnings Expected to Decline
by Zacks Equity Research
Exact Sciences (EXAS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Zacks Analyst Blog Highlights: Guardant, Illumina, Exact Sciences and Pfizer
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Guardant, Illumina, Exact Sciences and Pfizer
3 Stocks to Win Big in the Fight Against Cancer
by Tirthankar Chakraborty
We highlight three stocks that are using innovative ways to treat cancer, also called malignancy. These stocks are also great long-term investments.
The 5 Hottest Earnings Charts This Week
by Tracey Ryniec
These 5 stocks have had big rallies in 2019. Are they too hot to handle?
Earnings Preview: Exact Sciences (EXAS) Q1 Earnings Expected to Decline
by Zacks Equity Research
Exact Sciences (EXAS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Exact Sciences (EXAS) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
During Exact Sciences' (EXAS) first-quarter 2019 conference call, investor focus will be on the growth rate in the company's non-invasive screening test volume for colorectal cancer, Cologuard.
Should You Invest in the Invesco DWA Healthcare Momentum ETF (PTH)?
by Zacks Equity Research
Sector ETF report for PTH
Zacks Market Edge Highlights: Edwards Lifesciences, Exact Sciences, Aimmune Therapeutics, Allergan and Evolus
by Zacks Equity Research
Zacks Market Edge Highlights: Edwards Lifesciences, Exact Sciences, Aimmune Therapeutics, Allergan and Evolus
NASH, Allergies and Beauty Stocks: Invest or Not?
by Tracey Ryniec
There's a lot of innovation going on at the biopharmaceutical companies but which areas should investors be targeting?
Exact Sciences (EXAS) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Exact Sciences (EXAS) delivered earnings and revenue surprises of 12.00% and -0.01%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Options Traders Expect Huge Moves in Exact Sciences (EXAS) Stock
by Zacks Equity Research
Investors need to pay close attention to Exact Sciences (EXAS) stock based on the movements in the options market lately.
This Week's Hottest Earnings Charts
by Tracey Ryniec
Earnings season rolls on and these are the reports everyone will be watching.
Analysts Estimate Exact Sciences (EXAS) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Exact Sciences (EXAS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should You Invest in the Invesco DWA Healthcare Momentum ETF (PTH)?
by Zacks Equity Research
Sector ETF report for PTH
Is a Beat in Store for AbbVie (ABBV) This Earnings Season?
by Zacks Equity Research
AbbVie (ABBV) is likely to beat earnings in fourth quarter. Impressive sales of its key drug, Humira and strong growth of Imbruvica and Mavyret are expected to drive fourth-quarter sales.
Exact Sciences (EXAS) Is Up 16.34% in One Week: What You Should Know
by Zacks Equity Research
Does Exact Sciences (EXAS) have what it takes to be a top stock pick for momentum investors? Let's find out.
Are Options Traders Betting on a Big Move in Exact Sciences (EXAS) Stock?
by Zacks Equity Research
Investors need to pay close attention to Exact Sciences (EXAS) stock based on the movements in the options market lately.
Should You Invest in the Invesco DWA Healthcare Momentum ETF (PTH)?
by Zacks Equity Research
Sector ETF report for PTH
Exact Sciences (EXAS) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Exact Sciences (EXAS) delivered earnings and revenue surprises of 28.57% and 8.33%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?